Endovia Health Sciences, Inc.

Overview

Compare with Accredited Solutions, Inc., LQR House Inc. or MDWerks, Inc., or pick any stock.

• TickerEDVA on NYSE¹
• IndustryBeverages¹
• HeadquartersFort Lauderdale, Florida¹
• Incorporated inNV²
• Business address1112 N Flagler Drive, Fort Lauderdale, Fl 33304²
• Filer categoryNon-accelerated filer, Smaller reporting company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Endovia Health Sciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Endovia Health Sciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

We do not maintain a physical office. The address listed in this Report is a PO Box which receives our mail.

Item 2 of the 10-K filed Apr 15, 2026.¹²

Leadership

Who has led Endovia Health Sciences, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerBrady James Cobb Jun 10, 2026 to now¹³
• Chief executive officerRobert Nistico Apr 9, 2020 to Jun 10, 2026¹⁴
• Chief executive officerHeather Kearns Jul 10, 2019 to Jul 10, 2019¹⁵
• Chief executive officerMichael J. West Apr 10, 2014 to Apr 10, 2014¹⁶
• ChairRobert Nistico Apr 9, 2020 to now¹⁴
• PresidentWilliam R. Meissner Apr 19, 2022 to now¹⁷
• PresidentRobert Nistico Apr 9, 2020 to Mar 31, 2022¹⁴
• PresidentMichael J. West Apr 10, 2014 to Apr 10, 2014¹⁶
• Chief financial officerWilliam T. Devereux Oct 10, 2025 to now¹⁸
• Chief financial officerStacy B. McLaughlin Feb 26, 2024 to Feb 26, 2024¹⁹
• Chief financial officerJulius Paul Ivancsits May 6, 2024 to May 6, 2024²⁰
• Chief financial officerFatima Dhalla Feb 28, 2022 to Oct 16, 2023²¹
• Chief financial officerRonald Charles Wall Apr 25, 2022 to Aug 3, 2023²²
• Chief financial officerDean Scott Huge Apr 9, 2020 to Oct 19, 2020²³
• Chief financial officerStephen H. West Apr 9, 2014 to Apr 9, 2014²⁴
• Chief operating officerMichael Breen Bondurant Jun 15, 2026 to now²⁵

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerWilliam Devereaux named Jul 8, 2025³⁶
• DirectorBill Caple named Jul 8, 2025³⁶

Former names

• SPLASH BEVERAGE GROUP, INC.Aug 13, 2020 to Aug 21, 2026²
• Canfield Medical Supply, Inc.Jul 12, 2012 to Aug 5, 2020²

Timeline

1. Oct 15, 20268-K Entered a material agreement³⁷
2. Oct 6, 20268-K Unregistered sale of shares³⁸
3. Oct 5, 20268-K Regulation FD disclosure³⁹
4. Sep 24, 20268-K Entered a material agreement; Unregistered sale of shares⁴⁰
5. Sep 22, 20268-K Regulation FD disclosure⁴¹
6. Aug 31, 20268-K Regulation FD disclosure⁴²
7. Aug 28, 20268-K Unregistered sale of shares⁴³
8. Aug 26, 20268-K Entered a material agreement⁴⁴
9. Aug 25, 20268-K Regulation FD disclosure⁴⁵
10. Aug 21, 20268-K Regulation FD disclosure⁴⁶
11. Aug 20, 20268-K Results of operations⁴⁷
12. Aug 12, 20268-K Regulation FD disclosure⁴⁸
13. Jun 10, 2026New chief executive Brady James Cobb becomes CEO¹³
14. Apr 9, 2020New chief executive Robert Nistico becomes CEO¹⁴
15. Jul 10, 2019New chief executive Heather Kearns becomes CEO¹⁵
16. Apr 10, 2014New chief executive Michael J. West becomes CEO¹⁶

Calendar

Coming up

1. Nov 18, 2026Reports results for the quarter ending Sep/2026⁴⁹

When it reported results

1. Aug 20, 2026Reported quarterly or annual results⁴⁷
2. Aug 16, 2023Reported quarterly or annual results⁵⁰
3. Nov 17, 2022Reported quarterly or annual results⁵¹
4. Aug 16, 2022Reported quarterly or annual results⁵²
5. May 17, 2022Reported quarterly or annual results⁵³
6. Apr 1, 2022Reported quarterly or annual results⁵⁴
7. Nov 17, 2021Reported quarterly or annual results⁵⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

252 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 99 major events, 49 insider forms, 11 large holders, 5 private raises, 67 other. The latest 20:

1. Oct 15, 20268-K EDGAR
2. Oct 8, 2026DEFA14A EDGAR
3. Oct 6, 20268-K EDGAR
4. Oct 5, 2026DEF 14A EDGAR
5. Oct 5, 20268-K EDGAR
6. Sep 24, 20268-K EDGAR
7. Sep 23, 2026PRE 14A EDGAR
8. Sep 22, 20268-K EDGAR
9. Sep 18, 2026PRE 14A EDGAR
10. Aug 31, 20268-K EDGAR
11. Aug 28, 20268-K EDGAR
12. Aug 28, 2026424B3 EDGAR
13. Aug 26, 20268-K EDGAR
14. Aug 25, 20268-K EDGAR
15. Aug 24, 2026EFFECT EDGAR
16. Aug 21, 20268-K EDGAR
17. Aug 20, 2026S-1/A FORM S-1/A1 EDGAR
18. Aug 20, 20268-K EDGAR
19. Aug 19, 202610-Q EDGAR
20. Aug 17, 2026NT 10-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Aida AragonSCHEDULE 13G, 1 filing Nov 6, 2025⁵⁶
• Magdalene TongSCHEDULE 13G, 1 filing Oct 31, 2025⁵⁷
• Thomas Butler ForeSCHEDULE 13D, 1 filing Oct 31, 2025⁵⁸
• Robert NisticoSCHEDULE 13D, 1 filing Oct 27, 2025⁵⁹
• Frederick William CapleSCHEDULE 13D, 1 filing Oct 21, 2025⁶⁰
• Justin W. YorkeSCHEDULE 13D, 2 filings Apr 20, 2022 to Oct 21, 2025⁶¹
• William R. MeissnerSCHEDULE 13D, 1 filing Oct 21, 2025⁶²
• William T. DevereuxSCHEDULE 13D, 1 filing Oct 21, 2025⁶³
• L K Family Limited PartnershipSC 13G/A, 2 filings Nov 22, 2021 to Nov 16, 2022⁶⁴

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Jun 25, 2025Raised $33.3 million in a private offering of equity Form D: $36.2 million offered in all Form D
2. Aug 22, 2024Raised $600,000 in a private offering of securities Form D: 2 investors so far Form D
3. May 1, 2024Raised $1.9 million in a private offering of securities Form D: 3 investors so far Form D
4. Oct 5, 2023Raised $1.2 million in a private offering of securities Form D: 3 investors so far Form D
5. Dec 27, 2022Raised $4 million in a private offering of equity Form D: 8 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Endovia Health Sciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGAREndovia Health Sciences, Inc.¹
• CIK0001553788
• Employer ID (EIN)34-1720075¹²
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company¹²
• Incorporated inNevada¹²
• Fiscal year endsDecember 31¹
• Industry code (SIC)2080 Beverages¹
• SEC reviewing officeOffice of Manufacturing, Division of Corporation Finance¹
• Business address1112 N Flagler Drive, Fort Lauderdale, FL 33304¹
• Phone(954) 648-7238¹
• Shares outstanding6,412,521 as of Aug 19, 2026¹⁰
• Public float$6.5M as of Jun 30, 2025¹²
• AuditorRose, Snyder & Jacobs LLP, Encino, CA PCAOB ID 468; no auditor attestation of internal control over financial reporting¹²
• On EDGAR sinceJul 12, 2012¹
• Filings425 in all: 8-K (130), 10-Q (41), 4 (40), 3 (25), CORRESP (18), UPLOAD (17), 10-K (14), NT 10-Q (14)¹
  All 41 form types

  D (12), DEF 14A (9), PRE 14A (9), 424B3 (8), 8-K/A (8), EFFECT (8), S-1 (8), S-1/A (8), SCHEDULE 13D (6), NT 10-K (5), 10-Q/A (4), 424B5 (4), 10-K/A (3), DEF 14C (3), PRE 14C (3), DEFA14A (2), DEFR14A (2), DRS (2), PRER14A (2), RW (2), S-3 (2), S-8 (2), SC 13D (2), SC 14F1 (2), SCHEDULE 13G (2), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-A12G (1), CERT (1), SC 13D/A (1), SC 13G (1), SC 13G/A (1)

• Latest filingsAnnual report (10-K) Apr 15, 2026
  Quarterly report (10-Q) Aug 19, 2026
  Proxy statement (DEF 14A) Oct 5, 2026
  Latest 8-K (8-K) Oct 15, 2026

Securities registered for trading

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).¹²

Risk factors and legal proceedings

The risks Endovia Health Sciences, Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 42 risks under these headings, as written.¹²

• RISKS RELATED TO OUR BUSINESS
• Risks Related to our Financial Condition
• Our auditors have included an explanatory paragraph in their opinion regarding our ability to continue as a going concern. If we are unable to continue as a going concern, our stockholders will lose all or some of their investments.
• Because we lack the required $6 million of minimum stockholders’ equity currently as well at December 31, 2025, our Common Stock may be delisted by the NYSE American.
• Because we lack the capital to acquire inventory and market our products, we have generated no revenue in 2025 after the three months ended March 31, 2025, making our ability to remain in operation more difficult, and there are substantial doubts as to our ability to continue as a going concern.
• We have experienced recurring losses from operations and negative cash flows from operating activities and anticipate that we will continue to incur significant operating losses before reaching profitability.
• We may become subject to litigation in connection with our cancellation of the Series C that we had previously issued under the Asset Purchase Agreement related to certain water assets.
• Risks Related to our Business
• If we are unable to enter into a definitive agreement and close an acquisition of Medterra following our entry into a non-binding Letter of Intent on March 4, 2026 as described elsewhere in this Report, the Company and its stockholders will not receive the anticipated and intended benefits of such acquisition, and the Company would be forced to pursue alternative acquisitions or strategic transactions.
• Our strategic initiatives including acquisitions and divestitures may not be successful and may divert our management’s attention away from operations, and could create general customer uncertainty.
• If we fail to successfully integrate acquired assets or businesses, or if integrated, failure to further the Company’s business strategy, may result in the Company’s inability to realize any benefit from such acquisition or other adverse consequences.
• Demand for our products may be adversely affected by changes in consumer preferences or any inability on our part to innovate, market or distribute our products effectively, and any significant reduction in demand could adversely affect our business, financial condition or results of operations.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. Except for the litigation disclosed below, we are not currently a party to any legal or arbitration proceeding the outcome of which, if ‘determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business, operating results, cash flows, or financial condition.

On August 14, 2024, TapouT, LLC, (“TapouT”), filed a Complaint against the Company in the Supreme Count of New York for New York County (the “Court”). The Complaint pertains to breach of a certain Licensing Agreement dated December 8, 2011, under which the Company became a successor in interest on July 1, 2013, pursuant to an amendment to the Licensing Agreement.

The opening of Item 3, Legal Proceedings.¹²